Trials / Conditions / Gall Bladder Cancer

Gall Bladder Cancer

25 registered clinical trials studyying Gall Bladder Cancer — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary T NCT07454486	Aarhus University Hospital	—
Not Yet Recruiting	Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661	AccSalus Biosciences, Inc.	Phase 1
Recruiting	DESTINY-PANTUMOUR04 NCT07124000	AstraZeneca	—
Recruiting	Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174	First Affiliated Hospital of Zhejiang University	Phase 2
Recruiting	Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers NCT07337850	Tata Memorial Centre	—
Recruiting	Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanc NCT06852287	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572	Tata Memorial Centre	Phase 2 / Phase 3
Recruiting	Robotic-assisted Contra Open Resection for Suspected or Confirmed Gallbladder Cancer (ROBOCOP) NCT06246448	Karolinska University Hospital	N/A
Recruiting	Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277	University of California, Davis	N/A
Active Not Recruiting	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid NCT05712356	Lisata Therapeutics, Inc.	Phase 2
Enrolling By Invitation	Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Bi NCT06671418	Erasmus Medical Center	Phase 3
Active Not Recruiting	A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or NCT05506943	Compass Therapeutics	Phase 2 / Phase 3
Suspended	Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types NCT05000294	University of Florida	Phase 1 / Phase 2
Unknown	A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical NCT04856761	Fudan University	—
Recruiting	The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750	PMV Pharmaceuticals, Inc	Phase 1 / Phase 2
Completed	Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Ca NCT04164069	Anne Noonan	Phase 1
Completed	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene E NCT04426669	Intima Bioscience, Inc.	Phase 1 / Phase 2
Recruiting	A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening NCT07176962	Yingbin Liu, MD, PhD, FACS	—
Completed	Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor NCT03985072	Andes Biotechnologies	Phase 1
Unknown	Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos NCT03668418	University of Pisa	—
Withdrawn	Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD S NCT01875549	Kwang Hyuck Lee	N/A
Completed	B-Receptor Signaling in Cardiomyopathy NCT01135849	Daniel Bernstein	—
Terminated	Permission to Collect Blood Over Time for Research NCT00767234	Stanford University	—
Completed	Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-In NCT01016639	Lund University Hospital	Phase 1 / Phase 2
Completed	Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy NCT06631352	Seoul National University Hospital	—